Melanotan 2 Quick Reference (10 mg vial)
Research context: mechanisms, human and preclinical evidence, limitations and precautions are in How this works and References. The calculator (Spanish) converts any other volume.
Melanotan 2 Dosage Chart (10 mg vial)
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Titration (2 mL = ~5 mg/mL)
| Week / phase | Daily dose | Units per injection (mL) |
|---|---|---|
| Week 1 | 250 mcg | 5 units (0.05 mL) |
| Week 2 | 500 mcg | 10 units (0.10 mL) |
| Week 3 | 750 mcg | 15 units (0.15 mL) |
| Weeks 4–8 | 1 mg (1000 mcg) | 20 units (0.20 mL) |
| Maintenance (after Week 8) | 1 mg (1000 mcg) | 20 units (0.20 mL) |
Frequency: Once daily, subcutaneously, at a consistent time.
Note: Melanotan II is not approved by any regulatory agency; circulating schedules do not come from clinical trials.
Reconstitution Steps
- Draw 2 mL of bacteriostatic water with a sterile syringe.1
- Inject slowly down the vial wall; avoid shaking to prevent foaming.2
- Gently swirl or roll until fully dissolved (clear solution).3
- Label with the reconstitution date and refrigerate at 2–8 °C, protected from light; use within 4 weeks.4
Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
U-100 Conversion Table (2 mL = 5 mg/mL)
| U-100 units | Volume | Contains | Yield per vial |
|---|---|---|---|
| 2 | 0.02 mL | 100 mcg | 100 injections |
| 5 | 0.05 mL | 250 mcg | 40 injections |
| 10 | 0.10 mL | 500 mcg | 20 injections |
| 20 | 0.20 mL | 1 mg (1000 mcg) | 10 injections |
| 30 | 0.30 mL | 1.5 mg (1500 mcg) | 6 injections |
| 50 | 0.50 mL | 2.5 mg (2500 mcg) | 4 injections |
| 100 | 1.00 mL | 5 mg (5000 mcg) | 2 injections |
This section describes which dose a study or reference source used and what it measured. It is not a recommendation or an administration schedule. A trial dose belongs to its population, duration and supervision and does not transfer to anyone outside that context.
Supplies Needed
Straightforward 12- and 24-week planning for a 10 mg vial at 5 mg/mL.
Melanotan 2 vials (10 mg each)
- Standard / Gradual Titration, 12 weeks: Minimum 8 vials (73.5 mg required).
- Standard / Gradual Titration, 24 weeks: Minimum 16 vials (157.5 mg required).
U-100 syringes (1 mL)
- Standard / Gradual Titration, 12 weeks: 84 new syringes for 84 injections.
- Standard / Gradual Titration, 24 weeks: 168 new syringes for 168 injections.
Bacteriostatic water
- Standard / Gradual Titration, 12 weeks: 16 mL total (2 mL per vial) → 6 × 3 mL vials.
- Standard / Gradual Titration, 24 weeks: 32 mL total (2 mL per vial) → 11 × 3 mL vials.
Alcohol swabs
- Standard / Gradual Titration, 12 weeks: 168 minimum; one box of 100 does not cover the calculation.
- Standard / Gradual Titration, 24 weeks: 336 minimum; one box of 100 does not cover the calculation.
Sharps container: one appropriately sized. Stability planning: totals are minimum arithmetic quantities; follow the product documentation for sterility, storage, handling loss and discard timing.
Melanotan 2 10mgView in store
Bacteriostatic water 3 mLView in storeStore links may earn a commission. A supplier page is not scientific evidence or proof of suitability for human use.
Melanotan 2 Vial and Research Context
- Reconstitute: add 2 mL of bacteriostatic water to produce 5 mg/mL.
- Frequency in the source: once daily, subcutaneously.
- Described range: schedules run from 250 mcg to 1 mg (1000 mcg) per injection.
- Easy measuring: 1 U-100 unit = 0.01 mL = 50 mcg.
- Vial size: the 10 mg label is total nominal content, not a per-injection amount.
- Vial coverage: at 250 mcg per injection one vial supplies 40 injections; at 1 mg (1000 mcg) it supplies 10. These are mass calculations, not storage periods.
Protocol Overview
Quick reference for the schedules shared by the cited literature.
- Frequency: once daily.
- Concentration: 10 mg in 2 mL = 5 mg/mL.
- Unit conversion: 1 U-100 unit = 50 mcg.
Dosing Schedule
The tables keep each approach separate.
- Standard / Gradual Titration: 250 mcg, 500 mcg, 750 mcg, 1 mg (1000 mcg), 1 mg (1000 mcg), in phases (once daily).
- Measurement: use the units and mL shown beside each amount.
Storage Instructions
- Lyophilized (unopened): −20 °C for long-term storage; 2–8 °C if used within weeks. Protected from light.
- Reconstituted: 2–8 °C, do not freeze. Use within the documented period (typically up to 4 weeks with bacteriostatic water).
- Handling: do not shake; avoid temperature cycling; label with date and concentration.
- Discard: cloudy solutions, particulates or expired preparations are discarded.
More detail in the storage guide (Spanish).
Important Notes
- Research only: the referenced compounds are sold for laboratory research. Nothing here is medical advice or an administration schedule.
- Above 100 units: a 1 mL U-100 syringe cannot hold them; split across syringes or reconstitute with less volume.
- Accuracy: concentration depends on the actual volume added; measure the diluent with a syringe, not by eye.
- Verification: confirm vial contents against the batch certificate of analysis before calculating.
How This Works
- Activación de MC1R en melanocitos: stimulates the synthesis of eumelanin, the pigment responsible for dark colour and UV protection
- Activación de MC4R hipotalámica: reduce apetito y modula función sexual central
- Reducción de inflamación cutánea: side effect related to its kinship with α-MSH
- Modulación de termogénesis: mild impact on basal energy expenditure
Research Applications
- Safe tanning prior to sun exposure (original primary research)
- Erectile dysfunction resistant to PDE5 inhibitors
- Female sexual desire dysfunction
- Vitiligo (repigmentation research)
- Weight loss in preliminary research
Precautions Described in the Literature
Common adverse events: nausea (especially first doses), facial flushing, increased libido, darkening of pre-existing moles, appearance of new moles.
Punto crítico: dermatologically assess any new mole or change in existing moles during and after the protocol. Generalized melanocyte stimulation may darken pre-existing pigmented lesions, which could mask or mimic neoplastic changes.
Contraindications: active or suspected melanoma, family history of melanoma without prior dermatological evaluation, pregnancy and lactation.
Studied Combinations
- MT-2 + PT-141 for comprehensive sexual function coverage (complementary mechanisms)
- MT-2 + GHK-Cu for skin support during pigmentation
Injection Technique in Research
- Route in the studies: subcutaneous, in abdominal or thigh adipose tissue, rotating the site.
- Syringe: 1 mL U-100 (100 units); read in units, not mL.
- Asepsis: alcohol swab on the stopper and the site; a new syringe per injection.
- Drawing: purge air, draw the units from the chart and verify before withdrawing the needle from the vial.
Full guide: U-100 syringes and reading units (Spanish).
Research Note
All content on this page is technical and educational. It describes how a vial is reconstituted, how a syringe is read and which amounts the cited sources describe. It does not replace the supervision of a qualified researcher or the judgment of a health professional, and it is not intended to diagnose, treat, cure or prevent any disease.
References
- Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-1784.
- Wessells H, Levine N, Hadley ME, Dorr R, Hruby V. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000;12 Suppl 4:S74-79.
- Hadley ME, Hruby VJ. Discovery and development of novel melanogenic drugs. Pharm Biotechnol. 1998;11:545-575.